A BILL 
To amend title XIX of the Social Security Act to improve 
transparency and prevent the use of abusive spread pric-
ing and related practices in the Medicaid program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Drug Price Trans-
4
parency in Medicaid Act of 2019’’. 
5
SEC. 2. IMPROVING TRANSPARENCY AND PREVENTING THE 
6
USE OF ABUSIVE SPREAD PRICING AND RE-
7
LATED PRACTICES IN MEDICAID. 
8
(a) PASS-THROUGH PRICING REQUIRED.— 
9
23:41 Dec 06, 2019
H5281
2 
•HR 5281 IH
(1) IN GENERAL.—Section 1927(e) of the So-
1
cial Security Act (42 U.S.C. 1396r–8(e)) is amended 
2
by adding at the end the following: 
3
‘‘(6) PASS-THROUGH
PRICING
REQUIRED.—A 
4
contract between the State and a pharmacy benefit 
5
manager (referred to in this paragraph as a ‘PBM’), 
6
or a contract between the State and a managed care 
7
entity or other specified entity (as such terms are 
8
defined in section 1903(m)(9)(D)) that includes pro-
9
visions making the entity responsible for coverage of 
10
covered outpatient drugs dispensed to individuals en-
11
rolled with the entity, shall require that payment for 
12
such drugs and related administrative services (as 
13
applicable), including payments made by a PBM on 
14
behalf of the State or entity, is based on a pass- 
15
through pricing model under which— 
16
‘‘(A) any payment made by the entity or 
17
the PBM (as applicable) for such a drug— 
18
‘‘(i) is limited to— 
19
‘‘(I) ingredient cost; and 
20
‘‘(II) a professional dispensing 
21
fee that is not less than the profes-
22
sional dispensing fee that the State 
23
plan or waiver would pay if the plan 
24
23:41 Dec 06, 2019
H5281
3 
•HR 5281 IH
or waiver was making the payment di-
1
rectly; 
2
‘‘(ii) is passed through in its entirety 
3
by the entity or PBM to the pharmacy 
4
that dispenses the drug; and 
5
‘‘(iii) is made in a manner that is con-
6
sistent with section 1902(a)(30)(A) and 
7
sections 447.512, 447.514, and 447.518 of 
8
title 42, Code of Federal Regulations (or 
9
any successor regulation) as if such re-
10
quirements applied directly to the entity or 
11
the PBM; 
12
‘‘(B) payment to the entity or the PBM 
13
(as applicable) for administrative services per-
14
formed by the entity or PBM is limited to a 
15
reasonable administrative fee that covers the 
16
reasonable cost of providing such services; 
17
‘‘(C) the entity or the PBM (as applicable) 
18
shall make available to the State, and the Sec-
19
retary upon request, all costs and payments re-
20
lated to covered outpatient drugs and accom-
21
panying administrative services incurred, re-
22
ceived, or made by the entity or the PBM, in-
23
cluding ingredient costs, professional dispensing 
24
fees, administrative fees, post-sale and post-in-
25
23:41 Dec 06, 2019
H5281
4 
•HR 5281 IH
voice fees, discounts, or related adjustments 
1
such as direct and indirect remuneration fees, 
2
and any and all other remuneration; and 
3
‘‘(D) any form of spread pricing whereby 
4
any amount charged or claimed by the entity or 
5
the PBM (as applicable) is in excess of the 
6
amount paid to the pharmacies on behalf of the 
7
entity, including any post-sale or post-invoice 
8
fees, discounts, or related adjustments such as 
9
direct and indirect remuneration fees or assess-
10
ments (after allowing for a reasonable adminis-
11
trative fee as described in subparagraph (B)) is 
12
not allowable for purposes of claiming Federal 
13
matching payments under this title.’’. 
14
(2) 
CONFORMING
AMENDMENT.—Section 
15
1903(m)(2)(A)(xiii) 
of 
such 
Act 
(42 
U.S.C. 
16
1396b(m)(2)(A)(xiii)) is amended— 
17
(A) by striking ‘‘and (III)’’ and inserting 
18
‘‘(III)’’; 
19
(B) by inserting before the period at the 
20
end the following: ‘‘, and (IV) pharmacy benefit 
21
management services provided by the entity, or 
22
provided by a pharmacy benefit manager on be-
23
half of the entity under a contract or other ar-
24
rangement between the entity and the phar-
25
23:41 Dec 06, 2019
H5281
5 
•HR 5281 IH
macy benefit manager, shall comply with the re-
1
quirements of section 1927(e)(6)’’; and 
2
(C) by moving the left margin 2 ems to the 
3
left. 
4
(3) EFFECTIVE DATE.—The amendments made 
5
by this subsection apply to contracts between States 
6
and managed care entities, other specified entities, 
7
or pharmacy benefits managers that are entered into 
8
or renewed on or after the date that is 18 months 
9
after the date of enactment of this Act. 
10
(b) SURVEY OF RETAIL PRICES.— 
11
(1) IN GENERAL.—Section 1927(f) of the Social 
12
Security Act (42 U.S.C. 1396r–8(f)) is amended— 
13
(A) by striking ‘‘and’’ after the semicolon 
14
at the end of paragraph (1)(A)(i) and all that 
15
precedes it through ‘‘(1)’’ and inserting the fol-
16
lowing: 
17
‘‘(1) SURVEY
OF
RETAIL
PRICES.—The Sec-
18
retary shall conduct a survey of retail community 
19
drug prices, to include at least the national average 
20
drug acquisition cost, as follows: 
21
‘‘(A) USE
OF
VENDOR.—The Secretary 
22
may contract services for— 
23
‘‘(i) with respect to retail community 
24
pharmacies, the determination on a month-
25
23:41 Dec 06, 2019
H5281
6 
•HR 5281 IH
ly basis of retail survey prices of the na-
1
tional average drug acquisition cost for 
2
covered outpatient drugs for such phar-
3
macies, net of all discounts and rebates (to 
4
the extent any information with respect to 
5
such discounts and rebates is available), 
6
the average reimbursement received for 
7
such drugs by such pharmacies from all 
8
sources of payment, including third par-
9
ties, and, to the extent available, the usual 
10
and customary charges to consumers for 
11
such drugs; and’’; 
12
(B) by adding at the end of paragraph (1) 
13
the following: 
14
‘‘(F) SURVEY
REPORTING.—In order to 
15
meet the requirement of section 1902(a)(54), a 
16
State shall require that any retail community 
17
pharmacy in the State that receives any pay-
18
ment, administrative fee, discount, or rebate re-
19
lated to the dispensing of covered outpatient 
20
drugs to individuals receiving benefits under 
21
this title, regardless of whether such payment, 
22
fee, discount, or rebate is received from the 
23
State or a managed care entity directly or from 
24
a pharmacy benefit manager or another entity 
25
23:41 Dec 06, 2019
H5281
7 
•HR 5281 IH
that has a contract with the State or a man-
1
aged care entity, shall respond to surveys of re-
2
tail prices conducted under this subsection. 
3
‘‘(G) SURVEY INFORMATION.—Information 
4
on retail community prices obtained under this 
5
paragraph shall be made publicly available and 
6
shall include at least the following: 
7
‘‘(i) The monthly response rate of the 
8
survey including a list of pharmacies not in 
9
compliance with subparagraph (F). 
10
‘‘(ii) The sampling frame and number 
11
of pharmacies sampled monthly. 
12
‘‘(iii) 
Characteristics 
of 
reporting 
13
pharmacies, including type (such as inde-
14
pendent or chain), geographic or regional 
15
location, and dispensing volume. 
16
‘‘(iv) Reporting of a separate national 
17
average drug acquisition cost for each drug 
18
for independent retail pharmacies and 
19
chain operated pharmacies. 
20
‘‘(v) Information on price concessions 
21
including on and off invoice discounts, re-
22
bates, and other price concessions. 
23
‘‘(vi) Information on average profes-
24
sional dispensing fees paid. 
25
23:41 Dec 06, 2019
H5281
8 
•HR 5281 IH
‘‘(H) 
REPORT
ON
SPECIALTY
PHAR-
1
MACIES.— 
2
‘‘(i) IN GENERAL.—Not later than 1 
3
year after the effective date of this sub-
4
paragraph, the Secretary shall submit a re-
5
port to Congress examining specialty drug 
6
coverage and reimbursement under this 
7
title. 
8
‘‘(ii) CONTENT OF REPORT.—Such re-
9
port shall include a description of how 
10
State Medicaid programs define specialty 
11
drugs, how much State Medicaid programs 
12
pay for specialty drugs, how States and 
13
managed care plans determine payment for 
14
specialty drugs, the settings in which spe-
15
cialty drugs are dispensed (such as retail 
16
community pharmacies or specialty phar-
17
macies), whether acquisition costs for spe-
18
cialty drugs are captured in the national 
19
average drug acquisition cost survey, and 
20
recommendations as to whether specialty 
21
pharmacies should be included in the sur-
22
vey of retail prices to ensure national aver-
23
age drug acquisition costs capture drugs 
24
23:41 Dec 06, 2019
H5281
9 
•HR 5281 IH
sold at specialty pharmacies and how such 
1
specialty pharmacies should be defined.’’; 
2
(C) in paragraph (2)— 
3
(i) in subparagraph (A), by inserting 
4
‘‘, including payments rates under Med-
5
icaid managed care plans,’’ after ‘‘under 
6
this title’’; and 
7
(ii) in subparagraph (B), by inserting 
8
‘‘and the basis for such dispensing fees’’ 
9
before the semicolon; and 
10
(D) in paragraph (4), by inserting ‘‘, and 
11
$5,000,000 for fiscal year 2020 and each fiscal 
12
year thereafter,’’ after ‘‘2010’’. 
13
(2) EFFECTIVE DATE.—The amendments made 
14
by this subsection take effect on the first day of the 
15
first quarter that begins on or after the date that is 
16
18 months after the date of enactment of this Act. 
17
Æ 
23:41 Dec 06, 2019
H5281
